Aadi Bioscience Appoints David Dornan, PhD, as Chief Scientific Officer
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 18 2025
0mins
Source: PRnewswire
Appointment of New CSO: Aadi Bioscience has appointed Dr. David Dornan as Chief Scientific Officer, bringing over 20 years of experience in oncology and expertise in antibody-drug conjugates (ADCs) to advance the company's new ADC portfolio.
Strategic Developments: The company is implementing a strategic plan that includes selling FYARRO to Kaken Pharmaceuticals for $100 million, in-licensing a promising ADC portfolio from WuXi Biologics, and securing $100 million in private placement financing to support these initiatives.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
